IL22 and neoplasm: The addition of LR-IL-22 to a combined treatment modality with fractionated WAI and systemic chemotherapy and immunotherapy regimens will facilitate a safe and effective protocol for reducing tumor burden, increasing survival, and improving quality of life in patients with widespread abdominal ovarian cancer.